Detalhe da pesquisa
1.
Efficacy and Safety of a Recombinant Plant-Based Adjuvanted Covid-19 Vaccine.
N Engl J Med
; 386(22): 2084-2096, 2022 06 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35507508
2.
Efficacy, immunogenicity, and safety of a plant-derived, quadrivalent, virus-like particle influenza vaccine in adults (18-64 years) and older adults (≥65 years): two multicentre, randomised phase 3 trials.
Lancet
; 396(10261): 1491-1503, 2020 11 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33065035
3.
A plant-derived quadrivalent virus like particle influenza vaccine induces cross-reactive antibody and T cell response in healthy adults.
Clin Immunol
; 168: 72-87, 2016 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-26987887
4.
Influenza virus-like particle vaccines made in Nicotiana benthamiana elicit durable, poly-functional and cross-reactive T cell responses to influenza HA antigens.
Clin Immunol
; 154(2): 164-77, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-25128897
5.
Development and characterization of a plant-derived norovirus-like particle vaccine.
Vaccine
; 41(41): 6008-6016, 2023 09 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-37625992
6.
Lack of effects on female fertility or pre- and postnatal development of offspring in rats after exposure to AS03-adjuvanted recombinant plant-derived virus-like particle vaccine candidate for COVID-19.
Reprod Toxicol
; 107: 69-80, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34838689
7.
Broad neutralization against SARS-CoV-2 variants induced by ancestral and B.1.351 AS03-Adjuvanted recombinant Plant-Derived Virus-Like particle vaccines.
Vaccine
; 40(30): 4017-4025, 2022 06 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-35654621
8.
Safety, immunogenicity, and protection provided by unadjuvanted and adjuvanted formulations of a recombinant plant-derived virus-like particle vaccine candidate for COVID-19 in nonhuman primates.
Cell Mol Immunol
; 19(2): 222-233, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34983950
9.
Safety and immunogenicity of an AS03-adjuvanted plant-based SARS-CoV-2 vaccine in Adults with and without Comorbidities.
NPJ Vaccines
; 7(1): 142, 2022 Nov 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36351931
10.
Phase III: Randomized observer-blind trial to evaluate lot-to-lot consistency of a new plant-derived quadrivalent virus like particle influenza vaccine in adults 18-49 years of age.
Vaccine
; 39(10): 1528-1533, 2021 03 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33581920
11.
Safety and immunogenicity of a plant-derived rotavirus-like particle vaccine in adults, toddlers and infants.
Vaccine
; 39(39): 5513-5523, 2021 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34454786
12.
Development and characterization of a plant-derived rotavirus-like particle vaccine.
Vaccine
; 39(35): 4979-4987, 2021 08 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-34325930
13.
Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19.
Nat Med
; 27(6): 1071-1078, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34007070
14.
The production of hemagglutinin-based virus-like particles in plants: a rapid, efficient and safe response to pandemic influenza.
Plant Biotechnol J
; 8(5): 607-19, 2010 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-20199612
15.
Immunogenicity and safety of a quadrivalent plant-derived virus like particle influenza vaccine candidate-Two randomized Phase II clinical trials in 18 to 49 and ≥50 years old adults.
PLoS One
; 14(6): e0216533, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31166987
16.
The establishment of surrogates and correlates of protection: Useful tools for the licensure of effective influenza vaccines?
Hum Vaccin Immunother
; 14(3): 647-656, 2018 03 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29252098
17.
Humoral and cell-mediated immune responses to H5N1 plant-made virus-like particle vaccine are differentially impacted by alum and GLA-SE adjuvants in a Phase 2 clinical trial.
NPJ Vaccines
; 3: 3, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29387473
18.
MsCYS1, a developmentally-regulated cystatin from alfalfa.
Plant Physiol Biochem
; 45(6-7): 508-14, 2007.
Artigo
em Inglês
| MEDLINE | ID: mdl-17507234
19.
An in-built proteinase inhibitor system for the protection of recombinant proteins recovered from transgenic plants.
Plant Biotechnol J
; 4(3): 359-68, 2006 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-17147641
20.
Monoclonal C5-1 antibody produced in transgenic alfalfa plants exhibits a N-glycosylation that is homogenous and suitable for glyco-engineering into human-compatible structures.
Plant Biotechnol J
; 1(6): 451-62, 2003 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-17134403